Sequential molecularly targeted drug therapy including axitinib for a patient with end-stage renal failure and metastatic renal cell carcinoma

2015 ◽  
Vol 20 (2) ◽  
pp. E1-E4 ◽  
Author(s):  
Hayato Nishida ◽  
Hiroki Fukuhara ◽  
Atsushi Yamagishi ◽  
Toshihiko Sakurai ◽  
Tomohiro Shibasaki ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Renal Failure ◽  
Drug Therapy ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
End Stage Renal Failure ◽  
Targeted Drug ◽  
Molecularly Targeted Drug ◽  
End Stage

scholarly journals Efficacy of Nivolumab in a Patient with Metastatic Renal Cell Carcinoma and End-Stage Renal Disease on Dialysis: Case Report and Literature Review

2018 ◽  
Vol 2018 ◽  
pp. 1-4 ◽  
Author(s):  
Jawaher Ansari ◽  
Muhammad Ali ◽  
Ashraf Farrag ◽  
Arwa M. Ali ◽  
Abdulaziz Alhamad
Keyword(s):  
Renal Cell Carcinoma ◽  
Renal Disease ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
End Stage Renal Disease ◽  
Renal Cell ◽  
Pharmacokinetic Data ◽  
Management Options ◽  
Stage Renal Disease ◽  
End Stage

Treatment of patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease (ESRD) on dialysis poses a therapeutic challenge, particularly as this patient group was excluded from the pivotal clinical trials. In addition, there is uncertainty regarding drug dosing/pharmacokinetics, lack of safety and efficacy data, and potential for increased toxicity when using targeted therapy or immunotherapy for the management of patients with mRCC on dialysis. Nivolumab, an anti-programmed death-1 immune checkpoint inhibitor antibody, is indicated for the treatment of patients with mRCC who have received prior antiangiogenic therapy. Given the above-mentioned uncertainties, clinicians may be reluctant to use nivolumab for this patient population, leading to potential denial of life-prolonging medications. We report the case of a 72-year-old gentleman with mRCC and ESRD on dialysis who received second-line nivolumab therapy and achieved an excellent symptomatic and radiological response, remaining progression-free for over 22 months. In addition, we have reviewed the pharmacokinetic data and published retrospective case studies to review the management options for patients with mRCC and ESRD on dialysis.

Metastatic renal cell carcinoma to contralateral ureter presenting as acute obstructive renal failure after radical nephrectomy

Urology ◽  
2005 ◽  
Vol 65 (5) ◽  
pp. 1001 ◽  
Author(s):  
Eric K. Diner ◽  
Christopher R. Williams ◽  
Ashish Behari ◽  
Peter A. Pinto ◽  
W. Marston Linehan ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Renal Failure ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Radical Nephrectomy ◽  
Obstructive Renal Failure

Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study

2019 ◽  
Vol 17 (1) ◽  
pp. e150-e155 ◽  
Author(s):  
Cristina Masini ◽  
Maria Giuseppa Vitale ◽  
Marco Maruzzo ◽  
Giuseppe Procopio ◽  
Ugo de Giorgi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Renal Failure ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
First Line ◽  
Safety And Efficacy

Successful Sorafenib Treatment for Metastatic Renal Cell Carcinoma in a Case with Chronic Renal Failure

2009 ◽  
Vol 55 (4) ◽  
pp. 986-988 ◽  
Author(s):  
Sebastian Ruppin ◽  
Chris Protzel ◽  
Klaus-Jürgen Klebingat ◽  
Oliver W. Hakenberg
Keyword(s):  
Renal Cell Carcinoma ◽  
Renal Failure ◽  
Chronic Renal Failure ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Sorafenib Treatment

PD15-10 FEASIBILITY OF HIFU-TRIGGERED SORAFENIB-LOADED LIPOSOME NANOPARTICLES FOR TARGETED DRUG THERAPY IN RENAL CELL CARCINOMA

2015 ◽  
Vol 193 (4S) ◽  
Author(s):  
Caleb Abshire ◽  
James Liu ◽  
Jaspreet Arora ◽  
Hakm Murad ◽  
Sree Harsha Mandava ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Drug Therapy ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Targeted Drug
Sign in / Sign up

Export Citation Format

Share Document